Oral administration of biguanides (metformin) and sulfonylureas (gliclazide) are the most common approach of management of type 2 diabetes in humans. Among these diabetic patients, approximately 40–60% suffers from hypertension. Hence, the need of the day is application of polytherapy. A major challenge in polytherapy is the drug-drug interactions that may arise. Hence, this study is focused to develop a reverse phase high-performance liquid chromatography (RP-HPLC) method for concurrent estimation of diabetic drug metformin and hypertension drug valsartan using C18 column and find any possible pharmacokinetic interactions between the two drug combinations strategies, i.e., metformin-valsartan and gliclazide-valsartan in streptozotocin-induced diabetic rats. The bioanalysis of drug-drug interaction pharmacokinetic result showed no significant difference in the tmax of single treatment of gliclazide and single treatment of metformin or upon co-administration with valsartan. Our study has shown that polytherapy of valsartan, a drug administered for hypertension along with hypoglycemic drugs metformin and gliclazide, can be advantageous and safe in patients suffering from both diabetes and hypertension.

中文翻译：

---

缬沙坦联合二甲双胍和格列齐特在糖尿病大鼠模型中使用开发的 RP-HPLC 方法

口服双胍类（二甲双胍）和磺酰脲类（格列齐特）是治疗人类 2 型糖尿病的最常用方法。在这些糖尿病患者中，大约 40-60% 患有高血压。因此，今天的需要是应用综合疗法。综合疗法的一个主要挑战是可能出现的药物相互作用。因此，本研究的重点是开发一种使用 C18 柱同时评估糖尿病药物二甲双胍和高血压药物缬沙坦的反相高效液相色谱 (RP-HPLC) 方法，并找出两种药物组合策略之间任何可能的药代动力学相互作用，即、二甲双胍-缬沙坦和格列齐特-缬沙坦在链脲佐菌素诱导的糖尿病大鼠中。药物-药物相互作用药代动力学结果的生物分析显示，格列齐特单次治疗与二甲双胍单次治疗或与缬沙坦共同给药时的tmax无显着差异。我们的研究表明，缬沙坦（一种高血压药物）与降血糖药物二甲双胍和格列齐特联合治疗对糖尿病和高血压患者有益且安全。